Retatrutide

Retatrutide is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 4 labelled variants: 30mg, 20mg, 15mg, and 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, Retatrutide sits alongside Tesamorelin, Ipamorelin, and MOTS-c. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, Retatrutide is generally treated as a 36-amino acid GLP-1R/GIPR/GcgR triple agonist representing the first published peptide with balanced full agonism across all three incretin/glucagon-axis receptors. Retatrutide activates GLP-1R and GIPR via the same Gs-cAMP-PKA cascade as tirzepatide, while also engaging the glucagon receptor (GcgR), which adds pathway outputs relevant to hepatic glucose production and fatty acid oxidation assay models. Achieving balanced potency across three structurally similar class B GPCRs simultaneously required extensive sequence engineering — studies examining its binding mode at each receptor provide a useful platform for understanding receptor-selectivity determinants within the incretin peptide family.

The key research design challenge is separating the individual receptor contributions in cell systems that co-express some or all three targets. Selective antagonists or receptor-knockout models used alongside retatrutide enable attribution of specific readouts to each pathway, making comparator design more demanding but more informative than single-pathway assays. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Retatrutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

A product-specific COA is linked on this page, with purity noted as 99.554%. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare Retatrutide with Tesamorelin, Ipamorelin, and MOTS-c, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.